Compare AbbVie Inc (ABBV) vs iShares Core S&P 500 ETF (IVV) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

IVV, tracking the S&P 500, trades at $754.80, up 0.87% with a bullish technical signal from moving averages. The ETF shows strong institutional backing with $886 billion in assets and a low 0.03% expense ratio. Recent sector rotation has pressured tech stocks, but broader market optimism persists with analysts targeting S&P 500 levels up to 8,800 by year-end.

The outlook remains positive given strong earnings growth expectations and reasonable valuations, though concentration risk in top holdings and potential summer volatility pose near-term challenges. IVV offers efficient exposure to US large-caps, with dividend distributions providing additional return potential for long-term investors.